TY - JOUR
T1 - Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers
AU - Aronson, Matthew R.
AU - Dahl, Erika S.
AU - Halle, Jacob A.
AU - Simonson, Andrew W.
AU - Gogal, Rose A.
AU - Glick, Adam B.
AU - Aird, Katherine M.
AU - Medina, Scott H.
N1 - Funding Information:
We thank the laboratory of Dr. Joel Schneider at the National Cancer Institute for providing cancer cell lines. We also thank Dr. Matthew Taylor (Penn State University, College of Medicine, Hershey, PA) for donating the NL20 cell line. We thank the laboratories of Dr. Zissis Chroneos (Penn State University, College of Medicine, Hershey, PA), Dr. Pak Kin Wong (Penn State University, PA), and Dr. Kenneth Keiler (Penn State University, PA) for sharing the bacterial strains employed in these studies. We acknowledge and thank the Penn State Microscopy and Cytometry Facility—University Park, PA for assistance with confocal and electron microscopy. We also acknowledge the Penn State X-Ray Crystallography Facility—University Park, PA for use of the CD spectrophotometer. Funding for this research was provided by the Penn State Institute of Energy and the Environment Human Health and the Environment Seed Grant (S.H.M.), NIH:R00CA194309 (K.M.A.), NIH:F31CA236372 (E.S.D.), Penn State College of Engineering Grant (M.R.A.) and Penn State Graduate Research Fellowship (A.W.S.). Authors Matthew R. Aronson, Erika S. Dahl, Jacob A. Halle, Andrew W. Simonson, Rose A. Gogal, Adam B. Glick, Katherine M. Aird and Scott H. Medina declare they have no conflict of interest. No human studies were carried out by the authors for this article. No animal studies were carried out by the authors for this article.
Funding Information:
We thank the laboratory of Dr. Joel Schneider at the National Cancer Institute for providing cancer cell lines. We also thank Dr. Matthew Taylor (Penn State University, College of Medicine, Hershey, PA) for donating the NL20 cell line. We thank the laboratories of Dr. Zissis Chroneos (Penn State University, College of Medicine, Hershey, PA), Dr. Pak Kin Wong (Penn State University, PA), and Dr. Kenneth Keiler (Penn State University, PA) for sharing the bacterial strains employed in these studies. We acknowledge and thank the Penn State Microscopy and Cytometry Facility—University Park, PA for assistance with confocal and electron microscopy. We also acknowledge the Penn State X-Ray Crystallography Facility—University Park, PA for use of the CD spectrophotometer. Funding for this research was provided by the Penn State Institute of Energy and the Environment Human Health and the Environment Seed Grant (S.H.M.), NIH:R00CA194309 (K.M.A.), NIH:F31CA236372 (E.S.D.), Penn State College of Engineering Grant (M.R.A.) and Penn State Graduate Research Fellowship (A.W.S.).
Publisher Copyright:
© 2020, Biomedical Engineering Society.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Introduction: Bacteria and cancer cells share a common trait—both possess an electronegative surface that distinguishes them from healthy mammalian counterparts. This opens opportunities to repurpose antimicrobial peptides (AMPs), which are cationic amphiphiles that kill bacteria by disrupting their anionic cell envelope, into anticancer peptides (ACPs). To test this assertion, we investigate the mechanisms by which a pathogen-specific AMP, originally designed to kill bacterial Tuberculosis, potentiates the lytic destruction of drug-resistant cancers and synergistically enhances chemotherapeutic potency. Materials and Methods: De novo peptide design, paired with cellular assays, elucidate structure-activity relationships (SAR) important to ACP potency and specificity. Using the sequence MAD1, microscopy, spectrophotometry and flow cytometry identify the peptide’s anticancer mechanisms, while parallel combinatorial screens define chemotherapeutic synergy in drug-resistant cell lines and patient derived ex vivo tumors. Results: SAR investigations reveal spatial sequestration of amphiphilic regions increases ACP potency, but at the cost of specificity. Selecting MAD1 as a lead sequence, mechanistic studies identify that the peptide forms pore-like supramolecular assemblies within the plasma and nuclear membranes of cancer cells to potentiate death through lytic and apoptotic mechanisms. This diverse activity enables MAD1 to synergize broadly with chemotherapeutics, displaying remarkable combinatorial efficacy against drug-resistant ovarian carcinoma cells and patient-derived tumor spheroids. Conclusions: We show that cancer-specific ACPs can be rationally engineered using nature’s AMP toolbox as templates. Selecting the antimicrobial peptide MAD1, we demonstrate the potential of this strategy to open a wealth of synthetic biotherapies that offer new, combinatorial opportunities against drug resistant tumors.
AB - Introduction: Bacteria and cancer cells share a common trait—both possess an electronegative surface that distinguishes them from healthy mammalian counterparts. This opens opportunities to repurpose antimicrobial peptides (AMPs), which are cationic amphiphiles that kill bacteria by disrupting their anionic cell envelope, into anticancer peptides (ACPs). To test this assertion, we investigate the mechanisms by which a pathogen-specific AMP, originally designed to kill bacterial Tuberculosis, potentiates the lytic destruction of drug-resistant cancers and synergistically enhances chemotherapeutic potency. Materials and Methods: De novo peptide design, paired with cellular assays, elucidate structure-activity relationships (SAR) important to ACP potency and specificity. Using the sequence MAD1, microscopy, spectrophotometry and flow cytometry identify the peptide’s anticancer mechanisms, while parallel combinatorial screens define chemotherapeutic synergy in drug-resistant cell lines and patient derived ex vivo tumors. Results: SAR investigations reveal spatial sequestration of amphiphilic regions increases ACP potency, but at the cost of specificity. Selecting MAD1 as a lead sequence, mechanistic studies identify that the peptide forms pore-like supramolecular assemblies within the plasma and nuclear membranes of cancer cells to potentiate death through lytic and apoptotic mechanisms. This diverse activity enables MAD1 to synergize broadly with chemotherapeutics, displaying remarkable combinatorial efficacy against drug-resistant ovarian carcinoma cells and patient-derived tumor spheroids. Conclusions: We show that cancer-specific ACPs can be rationally engineered using nature’s AMP toolbox as templates. Selecting the antimicrobial peptide MAD1, we demonstrate the potential of this strategy to open a wealth of synthetic biotherapies that offer new, combinatorial opportunities against drug resistant tumors.
UR - http://www.scopus.com/inward/record.url?scp=85086857709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086857709&partnerID=8YFLogxK
U2 - 10.1007/s12195-020-00626-z
DO - 10.1007/s12195-020-00626-z
M3 - Article
C2 - 33184577
AN - SCOPUS:85086857709
SN - 1865-5025
VL - 13
SP - 447
EP - 461
JO - Cellular and Molecular Bioengineering
JF - Cellular and Molecular Bioengineering
IS - 5
ER -